Monday 15 December 2014

Roche biotech unit submits skin cancer drug application to U.S. regulator

ZURICH (Reuters) - Genentech, U.S. biotech unit of Swiss drugmaker Roche holding, said on Monday it had filed a marketing application to U.S. regulators for the use of its experimental drug in combination with another medicine to treat an advanced form of skin cancer. Cobimetinib is designed to be used with another Roche drug called Zelboraf for patients with tumors that have a mutation in a gene known as BRAF that allows melanoma cells to grow. ... via Health News Headlines - Yahoo News Read More Here..

No comments:

Post a Comment